Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib + Bendamustine + Obinutuzumab in Relapsed/Refractory Follicular Lymphoma
NCT03039114Phase 1Completed
- Sponsor
- Incyte
- Start
- Feb 2017
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of parsaclisib in follicular lymphoma (FL), sponsored by Incyte. Primary endpoint: Safety and tolerability of parsaclisib in combination with bendamustine and obinutuzumab at 34 months. Started Feb 2017; status: completed.
02
Drugs
parsaclisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03039114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03039114.